Liège, Belgium, September 23, 2022 – 17:45 CET – Mithra Pharmaceuticals SA (Euronext Brussels: MITRA) (the “Company” or “Mithra”), a company dedicated to women’s health, today announces that following of the Company’s first drawdown under the loan facility entered into with funds managed by Highbridge Capital Management, LLC (“Highbridge”) and funds managed by Whitebox Advisors, LLC (“Whitebox”, and jointly with Highbridge, each a “Lender”), a new part of the loans was contributed in kind by Highbridge against the issue of new shares.
Following the first drawing, a new part of the loans (including accrued interest, if any, and the option prepayment amount) was contributed in kind for a total amount of EUR 1,789,990.66 by l issue of 319,160 new shares at an issue price of approximately EUR 5.61 per share.